MA39193A1 - Modulateurs du gpr6 à base de tétrahydropyridopyrazines - Google Patents

Modulateurs du gpr6 à base de tétrahydropyridopyrazines

Info

Publication number
MA39193A1
MA39193A1 MA39193A MA39193A MA39193A1 MA 39193 A1 MA39193 A1 MA 39193A1 MA 39193 A MA39193 A MA 39193A MA 39193 A MA39193 A MA 39193A MA 39193 A1 MA39193 A1 MA 39193A1
Authority
MA
Morocco
Prior art keywords
tetrahydropyridopyrazines
gpr6
modulators based
gpr6 modulators
compounds
Prior art date
Application number
MA39193A
Other languages
English (en)
Other versions
MA39193B1 (fr
Inventor
Stephen Hitchcock
Holger Monenschein
Holly Reichard
Shota Kikuchi
Todd Macklin
Maria Hopkins
Jason Brown
Kristin Schleicher
Hukai Sun
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52440811&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39193(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MA39193A1 publication Critical patent/MA39193A1/fr
Publication of MA39193B1 publication Critical patent/MA39193B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des composés de formule (i) : qui sont utiles comme modulateurs du gpr6, des compositions pharmaceutiques les contenant, des procédés de traitement de maladies associées au gpr6, et des procédé de fabrication des composés et de leurs intermédiaires.
MA39193A 2013-12-20 2014-12-19 Modulateurs du gpr6 à base de tétrahydropyridopyrazines MA39193B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361919661P 2013-12-20 2013-12-20
PCT/US2014/071543 WO2015095728A1 (fr) 2013-12-20 2014-12-19 Modulateurs du gpr6 à base de tétrahydropyridopyrazines

Publications (2)

Publication Number Publication Date
MA39193A1 true MA39193A1 (fr) 2017-06-30
MA39193B1 MA39193B1 (fr) 2018-04-30

Family

ID=52440811

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39193A MA39193B1 (fr) 2013-12-20 2014-12-19 Modulateurs du gpr6 à base de tétrahydropyridopyrazines

Country Status (42)

Country Link
US (4) US9181249B2 (fr)
EP (2) EP3453709A1 (fr)
JP (1) JP6538697B2 (fr)
KR (1) KR102441531B1 (fr)
CN (2) CN108658978A (fr)
AR (2) AR098872A1 (fr)
AU (1) AU2014368992C1 (fr)
BR (1) BR112016014020B1 (fr)
CA (1) CA2934247C (fr)
CL (1) CL2016001595A1 (fr)
CR (1) CR20160321A (fr)
CY (1) CY1121395T1 (fr)
DK (1) DK3083620T3 (fr)
DO (1) DOP2016000144A (fr)
EA (1) EA032443B1 (fr)
EC (1) ECSP16061758A (fr)
ES (1) ES2702187T3 (fr)
GE (1) GEP201706783B (fr)
HR (1) HRP20182004T1 (fr)
HU (1) HUE042443T2 (fr)
IL (1) IL246177B (fr)
JO (1) JO3466B1 (fr)
LT (1) LT3083620T (fr)
MA (1) MA39193B1 (fr)
MX (1) MX2016008188A (fr)
MY (1) MY177031A (fr)
NZ (1) NZ721723A (fr)
PE (1) PE20160751A1 (fr)
PH (1) PH12016501192B1 (fr)
PL (1) PL3083620T3 (fr)
PT (1) PT3083620T (fr)
RS (1) RS58092B1 (fr)
SG (1) SG11201604921TA (fr)
SI (1) SI3083620T1 (fr)
SM (1) SMT201800668T1 (fr)
TN (1) TN2016000244A1 (fr)
TR (1) TR201900038T4 (fr)
TW (2) TWI809395B (fr)
UA (1) UA120427C2 (fr)
UY (1) UY35908A (fr)
WO (1) WO2015095728A1 (fr)
ZA (1) ZA201604703B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101939710B1 (ko) 2011-12-21 2019-01-17 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
JP6193374B2 (ja) 2012-08-13 2017-09-06 武田薬品工業株式会社 Ｇｐｒ６モジュレーターとしてのキノキサリン誘導体
UY34993A (es) 2012-08-28 2014-02-28 Janssen R & D Ireland Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
WO2014131847A1 (fr) 2013-02-28 2014-09-04 Janssen R&D Ireland Sulfamoyl-arylamides et leur utilisation en tant que médicaments pour le traitement de l'hépatite b
JP6419155B2 (ja) 2013-04-03 2018-11-07 ヤンセン・サイエンシズ・アイルランド・ユーシー Ｎ−フェニル−カルボキサミド誘導体およびｂ型肝炎を治療するための医薬品としてのその使用
HRP20181863T1 (hr) 2013-05-17 2018-12-28 Janssen Sciences Ireland Uc Derivati sulfamoiltiofenamida i njihova uporaba kao lijekova za liječenje hepatitisa b
JO3583B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
NO3024819T3 (fr) 2013-07-25 2018-07-21
MX368158B (es) 2013-10-23 2019-09-20 Janssen Sciences Ireland Uc Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
JO3466B1 (ar) * 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
WO2015120178A1 (fr) 2014-02-05 2015-08-13 Novira Therapeutics, Inc. Polythérapie pour le traitement d'infections par le vhb
DK3102572T3 (en) 2014-02-06 2019-02-04 Janssen Sciences Ireland Uc SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B
WO2015123505A1 (fr) * 2014-02-14 2015-08-20 Takeda Pharmaceutical Company Limited Modulateurs pyridopyrazines de gpr6
HK1247147A1 (zh) 2015-03-19 2018-09-21 诺维拉治疗公司 氮杂环辛烷和氮杂环壬烷衍生物以及治疗乙型肝炎感染的方法
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CN108430971A (zh) 2015-09-29 2018-08-21 诺维拉治疗公司 乙型肝炎抗病毒剂的晶体形式
KR20180129943A (ko) 2016-04-15 2018-12-05 노비라 테라퓨틱스, 인코포레이티드 캡시드 조립 억제제를 포함하는 배합물 및 방법
JOP20180057A1 (ar) * 2017-06-15 2019-01-30 Takeda Pharmaceuticals Co مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
JP2021515769A (ja) 2018-03-14 2021-06-24 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カプシド集合調節剤の投薬レジメン
US11096931B2 (en) 2019-02-22 2021-08-24 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
US11491148B2 (en) 2019-05-06 2022-11-08 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
WO2026067262A1 (fr) * 2024-09-26 2026-04-02 四川科伦药物研究院有限公司 Composé à cycles fusionnés, composition pharmaceutique le comprenant, utilisation et procédé

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4426296A (en) * 1994-08-11 1996-03-07 Takeda Chemical Industries Ltd. G protein coupled receptor protein, production, and use thereof
CN1364167A (zh) * 1999-02-26 2002-08-14 阿瑞那制药公司 G蛋白偶联受体6的小分子调节剂
AU2001239549A1 (en) 2000-03-24 2001-10-03 Akzo Nobel N.V. Keratinocyte growth inhibitors and hydroxamic acid derivatives
AU2003274005A1 (en) * 2002-10-24 2004-05-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 6 (gpr6)
US7388019B2 (en) 2003-01-31 2008-06-17 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
SE0400285D0 (sv) * 2004-02-10 2004-02-10 Astrazeneca Ab Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
NZ571540A (en) 2006-04-21 2010-10-29 Pfizer Prod Inc Pyridine[3,4-b]pyrazinones for inhibiting PDE-5
CA2651072A1 (fr) 2006-05-01 2007-11-08 Pfizer Products Inc. Composes heterocycliques 2-amino-substitues a cycles fusionnes
EP2153581B1 (fr) 2007-06-05 2013-07-31 Astrium Limited Système et procédé de test à distance
GB0710844D0 (en) 2007-06-06 2007-07-18 Lectus Therapeutics Ltd Potassium ion channel modulators & uses thereof
GB2449929A (en) 2007-06-08 2008-12-10 Snell & Wilcox Ltd Hierarchical spatial resolution building processes to fill holes in an interpolated image
FI2440546T3 (fi) 2009-06-12 2023-03-30 Abivax Ennenaikaisen vanhenemisen ja erityisesti progerian hoitamiseen hyödyllisiä yhdisteitä
WO2013087808A1 (fr) 2011-12-15 2013-06-20 Merz Pharma Gmbh & Co. Kgaa Composition pharmaceutique comprenant une pyrazolopyrimidine et une cyclodextrine
WO2013087815A1 (fr) 2011-12-15 2013-06-20 Merz Pharma Gmbh & Co. Kgaa Composition pharmaceutique liquide contenant un dérivé de pyrazolopyrimidine et utilisations pharmaceutiques de celle-ci
CA2872883A1 (fr) 2012-05-09 2013-11-14 Sunovion Pharmaceuticals Inc. Composes heteroaryles et leurs procedes d'utilisation
JP6193374B2 (ja) * 2012-08-13 2017-09-06 武田薬品工業株式会社 Ｇｐｒ６モジュレーターとしてのキノキサリン誘導体
FR2995937B1 (fr) 2012-09-21 2014-09-26 Exoes Ensemble de production d'electricite a moteur a pression de vapeur
JO3466B1 (ar) * 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6

Also Published As

Publication number Publication date
ES2702187T3 (es) 2019-02-27
BR112016014020B1 (pt) 2023-02-28
AU2014368992A1 (en) 2016-07-07
EP3453709A1 (fr) 2019-03-13
EP3083620A1 (fr) 2016-10-26
DK3083620T3 (en) 2019-01-14
MY177031A (en) 2020-09-02
DOP2016000144A (es) 2016-08-15
EP3083620B1 (fr) 2018-10-03
SG11201604921TA (en) 2016-07-28
US20180346464A1 (en) 2018-12-06
CL2016001595A1 (es) 2017-01-13
IL246177A0 (en) 2016-08-02
ECSP16061758A (es) 2018-02-28
PL3083620T4 (pl) 2019-09-30
NZ721723A (en) 2021-07-30
BR112016014020A2 (pt) 2017-08-08
TR201900038T4 (tr) 2019-01-21
RS58092B1 (sr) 2019-02-28
HUE042443T2 (hu) 2019-06-28
CN108658978A (zh) 2018-10-16
CA2934247C (fr) 2023-01-17
US9181249B2 (en) 2015-11-10
WO2015095728A1 (fr) 2015-06-25
SI3083620T1 (sl) 2019-02-28
US10077266B2 (en) 2018-09-18
PH12016501192A1 (en) 2016-08-15
EA201691272A1 (ru) 2017-05-31
US20170283414A1 (en) 2017-10-05
JP6538697B2 (ja) 2019-07-03
AR098872A1 (es) 2016-06-22
MA39193B1 (fr) 2018-04-30
US20160031881A1 (en) 2016-02-04
KR102441531B1 (ko) 2022-09-07
LT3083620T (lt) 2019-02-11
AU2014368992C1 (en) 2019-02-21
CY1121395T1 (el) 2020-05-29
BR112016014020A8 (pt) 2018-01-30
PE20160751A1 (es) 2016-08-01
CR20160321A (es) 2016-09-28
ZA201604703B (en) 2018-11-28
AR129635A2 (es) 2024-09-11
CN105829309A (zh) 2016-08-03
KR20160099705A (ko) 2016-08-22
TWI730937B (zh) 2021-06-21
US20150175602A1 (en) 2015-06-25
US10738046B2 (en) 2020-08-11
CN105829309B (zh) 2018-05-15
JO3466B1 (ar) 2020-07-05
GEP201706783B (en) 2017-11-27
PH12016501192B1 (en) 2016-08-15
UY35908A (es) 2015-07-31
TWI809395B (zh) 2023-07-21
CA2934247A1 (fr) 2015-06-25
EA032443B1 (ru) 2019-05-31
TW201605854A (zh) 2016-02-16
JP2017502027A (ja) 2017-01-19
SMT201800668T1 (it) 2019-01-11
AU2014368992B2 (en) 2018-09-13
US9708313B2 (en) 2017-07-18
UA120427C2 (uk) 2019-12-10
MX2016008188A (es) 2016-09-29
TW202202497A (zh) 2022-01-16
HRP20182004T1 (hr) 2019-02-08
IL246177B (en) 2019-11-28
PT3083620T (pt) 2019-01-17
PL3083620T3 (pl) 2019-09-30
TN2016000244A1 (en) 2017-10-06

Similar Documents

Publication Publication Date Title
MA39193B1 (fr) Modulateurs du gpr6 à base de tétrahydropyridopyrazines
MA35920B1 (fr) Composés destinés au traitement de l'amyotrophie spinale
MA42109A (fr) Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase
MX388682B (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
JOP20220119A1 (ar) أجسام مضادة trem2 واستخداماتها
MA34968B1 (fr) Urées asymétriques et utilisations médicales de celles-ci
MA37959A2 (fr) Dérivés de 5-phénoxy-3h-pyrimidin-4-one et leur utilisation en tant qu'inhibiteurs de la transcriptase inverse du vih
EA201690153A1 (ru) Замещенные бензофуранильные и бензоксазолильные соединения и их применения
EA201890239A2 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
EA201790273A1 (ru) Флагеллиновые композиции и их применение
MX353706B (es) Anticuerpos contra csf-1r humano y usos de los mismos.
EA201790070A1 (ru) Бифениламиды, содержащие модифицированные простые эфирные группы, в качестве ингибиторов hsp90 и стимуляторов hsp70
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
EA200971141A1 (ru) Соединения, активирующие теломеразу, и способы их применения
MX2018007075A (es) Compuestos policiclicos como inhibidores de tirosina quinasa de bruton.
MA39152A1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
EA201691141A1 (ru) Соединения против ccr6
PH12019501362A1 (en) Polymorphs
BR112014013138A2 (pt) anilinas substituídas como antagonistas de ccr(4)
EA201890898A1 (ru) Новые соединения и конъюгаты криптофицина, их получение и их терапевтическое применение
EA201790570A1 (ru) Модуляторы р2х7
MA40875A (fr) 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux
PH12020550947A1 (en) Polymorphs
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
MA39337A1 (fr) Modulateurs de pyrazines de gpr6